About Oxford BioMedica plc (LON:OXB)
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-56.98%
Return on Assets-11.53%
Frequently Asked Questions for Oxford BioMedica plc (LON:OXB)
What is Oxford BioMedica plc's stock symbol?
Oxford BioMedica plc trades on the London Stock Exchange (LON) under the ticker symbol "OXB."
Where is Oxford BioMedica plc's stock going? Where will Oxford BioMedica plc's stock price be in 2017?
3 Wall Street analysts have issued 12-month target prices for Oxford BioMedica plc's stock. Their predictions range from GBX 10.20 to GBX 13. On average, they expect Oxford BioMedica plc's stock price to reach GBX 12.07 in the next twelve months. View Analyst Ratings for Oxford BioMedica plc.
Who are some of Oxford BioMedica plc's key competitors?
Some companies that are related to Oxford BioMedica plc include Achaogen (AKAO), Karyopharm Therapeutics (KPTI), Clementia Pharmaceuticals (CMTA), Jounce Therapeutics (JNCE), Nightstar Therapeutics PLC Sponsored ADR (NITE), Sucampo Pharmaceuticals (SCMP), Synergy Pharmaceuticals (SGYP), Achillion Pharmaceuticals (ACHN), uniQure N.V. (QURE), BioCryst Pharmaceuticals (BCRX), Cytokinetics, Incorporated (CYTK), Kura Oncology (KURA), Atara Biotherapeutics (ATRA), GlycoMimetics (GLYC), Aurinia Pharmaceuticals (AUPH), Mersana Therapeutics (MRSN), NuCana PLC Sponsored ADR (NCNA) and NantKwest (NK).
Who are Oxford BioMedica plc's key executives?
Oxford BioMedica plc's management team includes the folowing people:
- John Dawson, Chief Executive Officer, Executive Director (Age 56)
- Stuart Paynter, Chief Financial Officer, Director
- Peter Nolan, Executive Director, Chief Business Officer (Age 62)
- Lorenzo Tallarigo M.D., Non-Executive Chairman of the Board (Age 64)
- Andrew J. Heath M.D., Ph.D., Non-Executive Deputy Chairman of the Board, Senior Independent Director (Age 66)
- Martin Diggle, Non-Executive Director (Age 52)
- Stuart Henderson, Non-Executive Director
How do I buy Oxford BioMedica plc stock?
Shares of Oxford BioMedica plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Oxford BioMedica plc's stock price today?
One share of Oxford BioMedica plc stock can currently be purchased for approximately GBX 8.55.
How big of a company is Oxford BioMedica plc?
Oxford BioMedica plc has a market capitalization of £264.10 million.
How can I contact Oxford BioMedica plc?
Oxford BioMedica plc's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000.
MarketBeat Community Rating for Oxford BioMedica plc (OXB)MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Oxford BioMedica plc (LON:OXB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||GBX 12.07|
Consensus Price Target History for Oxford BioMedica plc (LON:OXB)
Analysts' Ratings History for Oxford BioMedica plc (LON:OXB)
(Data available from 11/23/2015 forward)
|10/31/2017||Peel Hunt||Reiterated Rating||Buy||GBX 13|
|8/31/2017||N+1 Singer||Boost Price Target||Hold||GBX 8.70 -> GBX 10.20|
|8/31/2017||Jefferies Group LLC||Reiterated Rating||Buy||GBX 13|
|7/13/2017||Shore Capital||Reiterated Rating||not rated|
Earnings History for Oxford BioMedica plc (LON:OXB)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Oxford BioMedica plc (LON:OXB)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Oxford BioMedica plc (LON:OXB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oxford BioMedica plc (LON OXB)
Insider Trades by Quarter for Oxford BioMedica plc (LON OXB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/23/2017||Lorenzo Tallarigo||Insider||Buy||30,861||GBX 9||£2,777.49|
|10/23/2017||Lorenzo Tallarigo||Insider||Buy||30,436||GBX 9||£2,739.24|
|9/26/2017||Andrew Heath||Insider||Buy||110,511||GBX 9||£9,945.99|
|9/22/2017||Lorenzo Tallarigo||Insider||Buy||29,685||GBX 9||£2,671.65|
|9/15/2017||Martin Diggle||Insider||Buy||100,000||GBX 8||£8,000|
|9/1/2017||Martin Diggle||Insider||Buy||320,000||GBX 9||£28,800|
|8/31/2017||Martin Diggle||Insider||Sell||2,377,600||GBX 10||£237,760|
|7/17/2017||Peter Nolan||Insider||Buy||249,687||GBX 8||£19,974.96|
|7/13/2017||Martin Diggle||Insider||Buy||660,000||GBX 9||£59,400|
|6/23/2017||Lorenzo Tallarigo||Insider||Buy||49,033||GBX 5||£2,451.65|
|5/24/2017||Lorenzo Tallarigo||Insider||Buy||53,260||GBX 5||£2,663|
|4/24/2017||Lorenzo Tallarigo||Insider||Buy||54,090||GBX 5||£2,704.50|
|3/23/2017||Lorenzo Tallarigo||Insider||Buy||49,468||GBX 5||£2,473.40|
|2/24/2017||Lorenzo Tallarigo||Insider||Buy||67,165||GBX 4||£2,686.60|
|12/15/2016||Lorenzo Tallarigo||Insider||Buy||65,993||GBX 4||£2,639.72|
|11/25/2016||Lorenzo Tallarigo||Insider||Buy||75,417||GBX 4||£3,016.68|
|10/25/2016||Lorenzo Tallarigo||Insider||Buy||77,864||GBX 3||£2,335.92|
|9/26/2016||Lorenzo Tallarigo||Insider||Buy||79,988||GBX 3||£2,399.64|
|8/25/2016||Tallarigo ,Lorenzo||Insider||Buy||62,257||GBX 4||£2,490.28|
|7/25/2016||Tallarigo ,Lorenzo||Insider||Buy||63,351||GBX 4||£2,534.04|
|6/24/2016||Tallarigo ,Lorenzo||Insider||Buy||62,847||GBX 4||£2,513.88|
|5/13/2016||Diggle ,Martin||Insider||Buy||42,072||GBX 5||£2,103.60|
|5/12/2016||Diggle ,Martin||Insider||Buy||45,428||GBX 5||£2,271.40|
|5/5/2016||Diggle ,Martin||Insider||Buy||12,500||GBX 6||£750|
|5/4/2016||Diggle ,Martin||Insider||Buy||44,689||GBX 6||£2,681.34|
|5/3/2016||Diggle ,Martin||Insider||Buy||317,382||GBX 6||£19,042.92|
|4/22/2016||Tallarigo ,Lorenzo||Insider||Buy||41,083||GBX 6||£2,464.98|
|3/24/2016||Tallarigo ,Lorenzo||Insider||Buy||41,550||GBX 6||£2,493|
|2/26/2016||Diggle ,Martin||Insider||Buy||29,345||GBX 7||£2,054.15|
|2/25/2016||Tallarigo ,Lorenzo||Insider||Buy||36,370||GBX 7||£2,545.90|
|2/24/2016||Diggle ,Martin||Insider||Buy||46,693||GBX 6||£2,801.58|
|7/1/2015||Diggle ,Martin||Insider||Buy||284,439||GBX 0.09||£256|
|6/30/2015||Diggle ,Martin||Insider||Buy||775,000||GBX 0.09||£697.50|
|6/19/2015||Diggle ,Martin||Insider||Buy||225,000||GBX 0.08||£180|
|6/12/2015||Martin Diggle||Insider||Buy||283,978||GBX 9.01||£25,586.42|
|6/11/2015||Martin Diggle||Insider||Buy||416,022||GBX 9||£37,441.98|
|6/9/2015||Daniel Soland||Insider||Buy||500,000||GBX 9.45||£47,250|
|5/21/2015||Andrew Heath||Insider||Buy||100,000||GBX 10.60||£10,600|
|5/19/2015||Tim Watts||Insider||Buy||194,174||GBX 10.30||£19,999.92|
Latest Headlines for Oxford BioMedica plc (LON OXB)
|Lorenzo Tallarigo Acquires 30,861 Shares of Oxford BioMedica plc (OXB) Stock|
www.americanbankingnews.com - November 23 at 10:32 AM
|Is Oxford BioMedica PLC’s (LSE:OXB) Balance Sheet Strong Enough To Weather A Storm?|
finance.yahoo.com - November 10 at 9:33 AM
|OXB to present at Jefferies Healthcare Conference - London South East (blog)|
www.lse.co.uk - November 9 at 3:27 PM
|Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL - GlobeNewswire (press release)|
globenewswire.com - November 1 at 7:23 AM
|Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL|
feeds.benzinga.com - October 31 at 12:44 PM
|Oxford BioMedica plc (OXB) Insider Purchases £2,739.24 in Stock|
www.americanbankingnews.com - October 23 at 1:32 PM
|Andrew Heath Acquires 110,511 Shares of Oxford BioMedica plc (OXB) Stock|
www.americanbankingnews.com - September 26 at 1:28 PM
|Oxford BioMedica plc (OXB) Now Covered by Peel Hunt|
www.americanbankingnews.com - September 24 at 6:32 PM
|Lorenzo Tallarigo Buys 29,685 Shares of Oxford BioMedica plc (OXB) Stock|
www.americanbankingnews.com - September 22 at 10:27 AM
|Oxford BioMedica plc (OXB) Insider Martin Diggle Acquires 100,000 Shares|
www.americanbankingnews.com - September 15 at 10:27 AM
|Oxford BioMedica plc (OXB) Releases Earnings Results|
www.americanbankingnews.com - September 11 at 7:12 AM
|Oxford BioMedica plc (OXB) Insider Martin Diggle Sells 2,377,600 Shares|
www.americanbankingnews.com - September 5 at 10:34 AM
|Insider Buying: Oxford BioMedica plc (OXB) Insider Buys 320,000 Shares of Stock|
www.americanbankingnews.com - September 5 at 10:34 AM
|Oxford BioMedica plc (OXB) Scheduled to Post Earnings on Monday|
www.americanbankingnews.com - September 4 at 2:22 AM
|Oxford BioMedica plc (LON:OXB) Given New GBX 8.70 Price Target at N+1 Singer|
www.americanbankingnews.com - July 27 at 11:22 AM
|Peter Nolan Buys 249,687 Shares of Oxford BioMedica plc (LON:OXB) Stock|
www.americanbankingnews.com - July 17 at 11:29 AM
|Insider Buying: Oxford BioMedica plc (OXB) Insider Buys 660,000 Shares of Stock|
www.americanbankingnews.com - July 14 at 1:56 PM
|Oxford BioMedica plc's (LON:OXB) "Not Rated" Rating Reaffirmed at Shore Capital|
www.americanbankingnews.com - July 13 at 3:10 PM
|Oxford BioMedica plc (LON:OXB) Stock Rating Reaffirmed by N+1 Singer|
www.americanbankingnews.com - July 9 at 7:30 AM
|Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica - Financial Times|
www.ft.com - March 25 at 8:51 AM
|[$$] Investors Chronicle: Bellway, M&C Saatchi, Oxford Biomedica|
www.ft.com - March 24 at 6:58 PM
|Oxford BioMedica's (OXBDF) CEO John Dawson on Q4 2016 Results - Earnings Call Transcript|
seekingalpha.com - March 17 at 12:52 AM
|UK STOCKS-Factors to watch on March 16|
www.reuters.com - March 16 at 8:44 AM
|Full Year 2016 Oxford BioMedica PLC Earnings Release - Before Market Open|
biz.yahoo.com - March 16 at 8:44 AM
|Director Dealings / Market Share Purchase - London South East (registration) (blog)|
www.lse.co.uk - January 25 at 5:56 AM
|Findings Reported by Novartis on CTL-019 at ASH - London South East (registration) (blog)|
www.lse.co.uk - December 5 at 7:03 PM
|Result of General Meeting and Directors Dealing - London South East (registration) (blog)|
www.lse.co.uk - September 30 at 6:43 PM
Financials are not available for this stock.
Oxford BioMedica plc (LON OXB) Chart for Thursday, November, 23, 2017